AIM: To evaluate the cost effectiveness of surgery to remove intramural (IM) fibroids prior to assisted reproductive technology (ART). METHODS: The decision tree mathematical model along with sensitivity analysis was performed to analyze cost effectiveness of: (1) myomectomy followed by ART or (2) ART with IM myoma(s) in situ. RESULTS: At the median ongoing pregnancy (OP) rate (OPR) reported in the literature for a fresh, autologous ART cycle with IM fibroids in situ vs. post-IM myomectomy, average cost per OP was $72,355 vs. 66,075, indicating a cost savings with myomectomy. Sensitivity analysis over the range of reported OPRs demonstrated that pre-ART IM myomectomy was always cost effective when OPR among women with in situ myomas was <15.4%. However, for OPRs ≥15.4%, pre-ART IM myomectomy was only cost effective if it increased OPR by at least 9.6%. At the high end of OPRs reported for patients with IM myomas in situ (31.4%), a 19.5% improvement in OPR was needed to justify IM myomectomy from a cost perspective. CONCLUSION: Myomectomy should be used sparingly in cases where the goal of surgery is to achieve improvement in the outcomes of ART.
AIM: To evaluate the cost effectiveness of surgery to remove intramural (IM) fibroids prior to assisted reproductive technology (ART). METHODS: The decision tree mathematical model along with sensitivity analysis was performed to analyze cost effectiveness of: (1) myomectomy followed by ART or (2) ART with IM myoma(s) in situ. RESULTS: At the median ongoing pregnancy (OP) rate (OPR) reported in the literature for a fresh, autologous ART cycle with IM fibroids in situ vs. post-IM myomectomy, average cost per OP was $72,355 vs. 66,075, indicating a cost savings with myomectomy. Sensitivity analysis over the range of reported OPRs demonstrated that pre-ART IM myomectomy was always cost effective when OPR among women with in situ myomas was <15.4%. However, for OPRs ≥15.4%, pre-ART IM myomectomy was only cost effective if it increased OPR by at least 9.6%. At the high end of OPRs reported for patients with IM myomas in situ (31.4%), a 19.5% improvement in OPR was needed to justify IM myomectomy from a cost perspective. CONCLUSION: Myomectomy should be used sparingly in cases where the goal of surgery is to achieve improvement in the outcomes of ART.
Authors: Ben Kroon; Neil Johnson; Michael Chapman; Anusch Yazdani; Roger Hart Journal: Aust N Z J Obstet Gynaecol Date: 2011-03-22 Impact factor: 2.100
Authors: Luca Gianaroli; Stephan Gordts; Arianna D'Angelo; M Cristina Magli; Ivo Brosens; Carlo Cetera; Rudi Campo; Anna Pia Ferraretti Journal: Reprod Biomed Online Date: 2005-04 Impact factor: 3.828
Authors: Carlo Bulletti; Dominique DE Ziegler; Paolo Levi Setti; Ettore Cicinelli; Valeria Polli; Marco Stefanetti Journal: Ann N Y Acad Sci Date: 2004-12 Impact factor: 5.691
Authors: David W Lee; Teresa B Gibson; Ginger S Carls; Ronald J Ozminkowski; Shaohung Wang; Elizabeth A Stewart Journal: Fertil Steril Date: 2008-03-04 Impact factor: 7.329